EP2195002A4 - Erythropoietin receptor peptide formulations and uses - Google Patents
Erythropoietin receptor peptide formulations and usesInfo
- Publication number
- EP2195002A4 EP2195002A4 EP08796513A EP08796513A EP2195002A4 EP 2195002 A4 EP2195002 A4 EP 2195002A4 EP 08796513 A EP08796513 A EP 08796513A EP 08796513 A EP08796513 A EP 08796513A EP 2195002 A4 EP2195002 A4 EP 2195002A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- erythropoietin receptor
- receptor peptide
- peptide formulations
- formulations
- erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95739607P | 2007-08-22 | 2007-08-22 | |
US98975807P | 2007-11-21 | 2007-11-21 | |
PCT/US2008/070943 WO2009025958A1 (en) | 2007-08-22 | 2008-07-23 | Erythropoietin rceptor peptide formulations and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2195002A1 EP2195002A1 (en) | 2010-06-16 |
EP2195002A4 true EP2195002A4 (en) | 2011-09-07 |
Family
ID=40194013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08796513A Withdrawn EP2195002A4 (en) | 2007-08-22 | 2008-07-23 | Erythropoietin receptor peptide formulations and uses |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2195002A4 (en) |
JP (2) | JP2010536857A (en) |
WO (2) | WO2009025958A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2709648A4 (en) * | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | Compounds that bind to the erythropoietin receptor |
AU2015267501A1 (en) * | 2014-05-28 | 2016-12-08 | The Board Of Regents Of The University Of Texas System | Novel compounds supports hematopoietic stem cells and red blood cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004101606A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
WO2006133144A2 (en) * | 2005-06-03 | 2006-12-14 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US20070027074A1 (en) * | 2003-05-12 | 2007-02-01 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
WO2006136821A1 (en) * | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
-
2008
- 2008-07-23 EP EP08796513A patent/EP2195002A4/en not_active Withdrawn
- 2008-07-23 JP JP2010521912A patent/JP2010536857A/en active Pending
- 2008-07-23 WO PCT/US2008/070943 patent/WO2009025958A1/en active Application Filing
- 2008-07-23 JP JP2010521913A patent/JP2010536858A/en active Pending
- 2008-07-23 WO PCT/US2008/070926 patent/WO2009025957A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004101606A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
US20070027074A1 (en) * | 2003-05-12 | 2007-02-01 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
WO2006133144A2 (en) * | 2005-06-03 | 2006-12-14 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
Non-Patent Citations (5)
Title |
---|
FAN ET AL: "Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 34, no. 10, 1 October 2006 (2006-10-01), pages 1303 - 1311, XP005656813, ISSN: 0301-472X * |
GLASPY J A: "THE DEVELOPMENT OF ERYTHROPOIETIC AGENTS IN ONCOLOGY", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 3, 1 January 2005 (2005-01-01), pages 553 - 567, XP008074550, ISSN: 1472-8214 * |
REDDY G K ET AL: "Preliminary results of a phase II dose-finding study of subcutaneous Hematide(TM) in patients with cancer receiving chemotherapy", SUPPORTIVE CANCER THERAPY 200701 US, vol. 4, no. 2, January 2007 (2007-01-01), pages 74 - 75, XP001539117, ISSN: 1543-2912 * |
See also references of WO2009025958A1 * |
WOODBURN ET AL: "Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 35, no. 8, 26 July 2007 (2007-07-26), pages 1201 - 1208, XP022171067, ISSN: 0301-472X * |
Also Published As
Publication number | Publication date |
---|---|
WO2009025957A1 (en) | 2009-02-26 |
JP2010536857A (en) | 2010-12-02 |
EP2195002A1 (en) | 2010-06-16 |
JP2010536858A (en) | 2010-12-02 |
WO2009025958A1 (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248128A0 (en) | Stabilized receptor polypeptides and uses thereof | |
IL187354A0 (en) | Erythropoietin receptor peptide formulations and uses | |
HK1222333A1 (en) | Peptide slow-release formulations | |
IL203173A (en) | Cationic peptides and compositions thereof | |
EP2225275A4 (en) | Protein formulation | |
HRP20130109T1 (en) | Caspofungin formulations | |
EP2142572A4 (en) | Tgfp-cap peptide and its uses | |
GB0716385D0 (en) | Formulations | |
HK1145506A1 (en) | Peptides and their use | |
GB0712670D0 (en) | Isolated peptides and uses thereof | |
ZA200908969B (en) | Formulations | |
GB0708376D0 (en) | Novel polypeptides and uses thereof | |
HRP20150195T1 (en) | Peptides and their use | |
GB0809979D0 (en) | Formulations | |
GB0711957D0 (en) | Formulations | |
GB0702022D0 (en) | Peptides and their use | |
HK1217912A1 (en) | Controlled-released peptide formulations | |
GB0810232D0 (en) | Formulations | |
EP2123666A4 (en) | Peptide | |
EP2285827A4 (en) | Peptides and uses thereof | |
EP2195002A4 (en) | Erythropoietin receptor peptide formulations and uses | |
ZA201006443B (en) | Novel immunoregularory peptides,compositions and uses thereof | |
GB0703945D0 (en) | Peptide | |
GB0705179D0 (en) | Formulations | |
GB0710813D0 (en) | Peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100319 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110808 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 7/06 20060101ALI20110802BHEP Ipc: C07K 14/505 20060101ALI20110802BHEP Ipc: A61K 47/48 20060101ALI20110802BHEP Ipc: A61K 38/17 20060101ALI20110802BHEP Ipc: A61K 38/16 20060101AFI20110802BHEP |
|
17Q | First examination report despatched |
Effective date: 20140203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140614 |